Mobile

Part 1: An open Label Pilot Study to Determine Interstitial and Tissue Concentrations of Aliskiren and Effects on the Renin-Angiotensin System (RAS) in Fat and Skeletal Muscle of Hypertensive Patients...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-004566-16

Part 1: An open Label Pilot Study to Determine Interstitial and Tissue Concentrations of Aliskiren and Effects on the Renin-Angiotensin System (RAS) in Fat and Skeletal Muscle of Hypertensive Patients with Abdominal Obesity Part 2: A Randomized, Double Blind, 12-weeks Parallel Group Study to Compare Effects of Aliskiren 300 mg and Amlodipine 5 mg on the RAS and Lipid/Carbohydrate Metabolism in Fat and Skeletal Muscle of Hypertensive Patients with Abdominal Obesity

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Part 1 - Quantify the concentration of aliskiren, amlodipine and angiotensin II (Ang II) in interstitial fluid (microdialysis), and quantify the concentration of aliskiren, angiotensin II and renin concentration and activity in the plasma and in the tissue (biopsy) of subcutaneous fat and skeletal muscle in hypertensive patients with abdominal obesity. Part 2 (depending on the successful results of part 1): Compare the effects of aliskiren and amlodipine on Ang II in interstitial fluid of subcutaneous fat and skeletal muscle and on RAS biomarkers in the plasma from hypertensive patients with abdominal obesity.

Critère d'inclusion

  • Hypertension

Liens